Machine clearance doesn't mean the PRP shot will help

The label covers the machine, not your result

PRP uses blood taken from you. A clinician draws it, and then a fast-spinning machine divides the blood into layers. The shot uses a layer with more platelets, small parts in blood that gather over a cut. A provider puts that layer inside your aching joint or into the rope-like tissue linking muscle and bone. That’s the machine’s only part in the treatment.

The limit matters.

A sales sheet might call its blood machine cleared. That claim doesn’t prove the shot will ease your knee or shoulder. The exam and the reason for the ache matter more. I’d want a clinician to tell me what’s known for my kind of soreness. I’d also ask what nobody knows yet.

The sore joint should come first at the visit

During a QC Kinetix visit, you can ask about regenerative treatments, the clinic’s term for non-surgical shots its team prepares from your blood. Medical providers are the people who examine you and handle the treatment. They can talk about PRP after checking the joint. You’ll want to ask why the shot is being considered and whether simpler care still fits.

What counts is the reason for the soreness, not a label on equipment.

Payment is another question. Insurance may refuse the bill even when a clinician thinks the shot is reasonable. If insurance paid, that still wouldn’t prove you’ll improve. Keep three facts apart: the machine’s use, the exam finding, and how people with similar soreness fared. Nobody can tell you the outcome beforehand.

Sources

1. The devices used to spin PRP at the point of care are cleared by FDA as clinical centrifuges, product code JQC, a Class I device under 21 CFR 862.2050 - for example the Biomet GPS Platelet Separation Kit (K030555, cleared 2003) and the Harvest SmartPrep2 / SmartPrep Platelet Concentration System (K103340, cleared 2010). That clearance covers the equipment that separates blood. It is not an FDA approval of platelet-rich plasma as a treatment for osteoarthritis, tendinopathy or any other orthopedic condition, and copy must never blur the two.

   U.S. Food and Drug Administration (Center for Devices and Radiological Health) — 510(k) Premarket Notification database and Product Classification: JQC, Centrifuges (Micro, Ultra, Refrigerated) For Clinical Use, 21 CFR 862.2050. FDA accessdata (CDRH device databases), 2003.

2. FDA states verbatim of stem cell, stromal vascular fraction, umbilical cord blood, Wharton's jelly, amniotic fluid and exosome products: 'None of these products have been approved for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain.' The only FDA-approved stem cell products in the United States are blood-forming cells from umbilical cord blood, approved only for disorders of blood production, and there are no FDA-approved exosome products. PRP is a different product from all of these and the categories must not be blurred in either direction.

   U.S. Food and Drug Administration — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA (Center for Biologics Evaluation and Research), 2020.

3. Medicare's national coverage policy covers autologous platelet-rich plasma ONLY for patients with chronic non-healing diabetic, pressure and/or venous wounds, and only within an approved coverage-with-evidence-development clinical study. There is no Medicare national coverage for PRP in osteoarthritis or tendinopathy, which is why these injections are billed to the patient as cash-pay.

   Centers for Medicare & Medicaid Services — Autologous Platelet-rich Plasma (Coverage with Evidence Development). CMS.gov, 2024.

4. In January 2025 the FTC and the Georgia Attorney General obtained federal court orders permanently BANNING the co-founders of the Stem Cell Institute of America and related companies from marketing stem cell therapy, plus $5,155,146 in civil penalties and consumer refunds. The court found on summary judgment that the defendants published false and misleading advertisements about the efficacy and approval of stem cell injections for conditions including osteoarthritis; the affiliated clinic had charged up to $5,000 per injection, almost exclusively to elderly and disabled consumers.

   Federal Trade Commission — Stem Cell Institute Co-Founders and Companies Banned from Marketing Stem Cell Treatments and Ordered to Pay More Than $5.1 Million for Refunds and Civil Penalties. FTC Press Release, 2025.

5. A web surveillance study of regenerative medicine clinics in the US-Mexico border region found 99.1% of the clinic websites mentioned no affiliation with an academic institution or other overt token of scientific legitimacy, 67.3% claimed autologous tissue as the source of treatment, and most did not specify the route of administration. Of the Tijuana clinics identified, 13 claimed licensing but only one matched available licensing records.

   Chavez J, Shah NA, Ruoss S, et al. — Online marketing practices of regenerative medicine clinics in US-Mexico border region: a web surveillance study. Stem Cell Research & Therapy, 2021. DOI: 10.1186/s13287-021-02254-4.

6. The Cochrane review of STEM CELL injections for knee osteoarthritis concluded that on low-certainty evidence they may slightly improve pain and function, with uncertainty about effects on quality of life, treatment success and structural progression, and uncertainty about safety. This matters on a PRP site because 'stem cell therapy' is routinely used as a marketing label for PRP; they are different products with different evidence and PRP must never be described as a stem cell treatment.

   Whittle SL, Johnston RV, McDonald S, et al. — Stem cell injections for osteoarthritis of the knee. Cochrane Database of Systematic Reviews, 2025. DOI: 10.1002/14651858.CD013342.pub2.